CURRICULUM VITAE Jeffrey C. Fink, M.D., M.S. Professor, Department of Medicine and Epidemiology (secondary) University of Maryland School of Medicine
Education 1979 - 1983
B.A.
Clark University, Worcester, Massachusetts
1983 - 1987
M.D. Case Western University School of Medicine, Cleveland, Ohio
1994 - 1996
M.S.
Master of Science Program, Department of Epidemiology School of Public Health and Community Medicine University of Washington, Seattle, Washington
Post Graduate Education 1987 - 1990
Intern and Resident in Medicine University of Washington Seattle, Washington
1993 - 1994
Clinical Fellow, Division of Nephrology University of Washington Seattle, Washington
1994 - 1996
Research Fellow, Division of Nephrology University of Washington Seattle, Washington
Certifications 1990-2000 1996-2006 2000-2010 2000-2014
Diplomate, American Board of Internal Medicine Diplomate, American Board of Internal Medicine, Nephrology Recertified, Diplomate, American Board of Internal Medicine Recertified, American Board of Internal Medicine, Nephrology
Medical Licensures 1987 - 1990 1990 - 1992 1992 - 1993
Washington (inactive) Massachusetts (inactive) California (inactive)
Jeffrey C. Fink, M.D., M.S. Page 2 of 19 1993 - 1996 1996 - present
Washington (inactive) Maryland (active)
Employment History Academic Appointments 1990 - 1992
Assistant Professor of Medicine Division of General Internal Medicine, Department of Medicine Tufts University School of Medicine, Boston, MA
1992 - 1993
Assistant Professor of Medicine Division of General Internal Medicine, Department of Medicine University of Southern California, Los Angeles, CA
1996 -2002
Assistant Professor, Departments of Medicine and Epidemiology Division of Nephrology University of Maryland School of Medicine (UMSOM), Baltimore, MD
2002 - 2011
Associate Professor, Departments of Medicine and Epidemiology (secondary) Division of Nephrology (UMSOM)
July 2011-
Professor, Department of Medicine and Epidemiology (secondary) Division of Nephrology (UMSOM)
Other Employment 1990 - 1992
Staff Physician New England Medical Center, Boston, MA
1992 - 1993
Staff Physician University of Southern California Medical Center Los Angeles County Medical Center, Los Angeles, CA
1996 - present
Staff Physician University of Maryland Medical Center (UMMC) Baltimore VA Medical Center, (BVMAC), Baltimore, MD
Professional Society Memberships 1990 - present 1993 - present 1993 - present 1999 - 2007
American College of Physicians National Kidney Foundation American Society of Nephrology American Society of Transplantation
Jeffrey C. Fink, M.D., M.S. Page 3 of 19 2001 - 2007
American Heart Association
Honors and Awards 1982 1999 2005 2011
Phi Beta Kappa, Clark University American Society of Nephrology, Carl W. Gottschalk Research Award Fellow, American Society of Nephrology Fellow, National Kidney Foundation
Clinical Activities 2000 - present
Founder and Director, Early Renal Insufficiency (ERI) Program UMMC ERI Clinic Over 800 patients seen since inception with 250 active patients per year Pilot site for NIH National Kidney Disease Education Program educational outreach activities Platform for multiple clinical research activities Showcase program for junior faculty recruitment Duties: 0.5 day clinic; 0.25 day administrative
2001 - present
BVAMC ERI clinic Over 1200 patients seen since inception with 530 active patients per year Extension of Early Renal Insufficiency (ERI) program from UMMS Platform for multiple clinical research activities Duties: 0.5 + 0.25 day clinic; 0.25 day administrative
Administrative Services Institutional Service (University of Maryland) 2000-2002 School of Medicine Dean’s Council 2001 Faculty Practice Office, Space Committee 2005-2007 Faculty Senate 2006-present Institutional Review Board 2006-present GCRC Advisory Committee 2008 Director, Baltimore VA Pre-transplant services Local and National Service 1992 1997 - 2007 1997 - 2006 2001 - 2004 2001 - 2002 2001 - 2002 2002
Expert Witness for United States Attorney, U.S. vs. Smushkevich, et al. National Kidney Foundation of Maryland, Medical Advisory Board Mid-Atlantic Renal Coalition, Medical Research Board National Kidney Foundation of Maryland, Grant Review Committee American Society of Nephrology, Clinical Science Committee Editorial Board, American Journal of Kidney Disease National Kidney Foundation, Career Development Grant Review Committee
Jeffrey C. Fink, M.D., M.S. Page 4 of 19 2002 - 2010 2002 - present 2003 - 2004 2004 - 2007 2004 - 2009 2006 - present 2006 - present 2008 2008 2009 2009 - present 2009 - present 2009 - 2010 2009 2009 2009 2009 - present 2010 – present 2010
Maryland Kidney Commission, (Chair 2002-2006; 2009 - 2010) NIDDK Chronic Renal Insufficiency Cohort (CRIC) Steering Committee National Kidney Disease Education Program, Baltimore Co-Chairman Editorial Board, Journal of the American Society of Nephrology American Society of Nephrology, Chronic Kidney Disease Advisory Committee Paul Teschan Research Fund Grant Reviewer NIDDK Data Safety and Monitoring Board (DSMB) for Clinical Trial of Oral versus IV Iron in CKD Patients (PI Agarwal) NIH Special Emphasis Scientific Review Group Ancillary Studies in the Natural History of Acute Kidney Injury ZDK1 GRB-7 (M1) NIH Scientific Review Group Pilot and Feasibility Grants in Kidney Disease (PAR 06-113) ZRG1 RUS-F S (7/24/08) NIH Scientific Review Group Nephrology and Urology Clinical and Small Business Grants 2009/05 ZRG1 DKUS-G (51) S (4/6-4/7) Associate Editor, American Journal of Kidney Disease Editorial Board, Clinical Nephrology American Society of Nephrology, Clinical Science Committee NIH Scientific Review Group, Chair Pilot and Feasibility Grants in Kidney and Urological Disease ZRG1 DKUS-G (51) (10/08-10/13) NIH Scientific Review Group CKD Biomarkers Ancillary Studies ZDK1 GRB-6 (J1) 1 (11/16) NIH Scientific Review Group NIDDK R01 Ancillary Studies ZDK1 GRB-G (J4) 1 (11/20/09) NIDDK CRIC Study Publication Executive Committee (Co-chair) Associate Editor, Clinical Journal of the American Society of Nephrology ZDK1 GRB-7 (J3) (12/07/10) NIH Scientific Review Group Pediatric Ancillary Study to ASSESS-AKI
Teaching Service Residents/Fellows 1996 - 1998
Attending on UMMC Medical Service, 1 month per year Conducted daily teaching rounds and weekly lectures, 2 hours per day 4 medical residents per month
2007 - present
Attending on Medical Service, BVAMC 1 month per year Conducted daily teaching rounds and weekly lectures
Jeffrey C. Fink, M.D., M.S. Page 5 of 19 4 medical residents per month
2007 - present
Attending on Transplant Service, UMMC 1 month per year Conduct daily teaching rounds 2 surgical residents in conjunction with surgery attending, 1 hour per day
1996 – 1998
Renal Journal Club Lead 3 to 4 one hour conferences per year; attended by 3-4 nephrology fellows
Students 1996 – 1998
Attending on UMMC Medical Service, 1 month per year Conducted daily teaching rounds and weekly lectures, 2 hours per day 2 third yr medical students per month
2007 - present
Attending on Medical Service, BVAMC, 1 month per year Conducted daily teaching rounds and weekly lectures, 2 hours per day 2 third yr medical students, and 1 fourth yr medical student per month
1997 - 2000
Small Group Leader, Renal Pathophysiology and Therapeutics Lead 3 small group sessions per year, 2 hours per session Attended by 5-10 second year medical students
1997 - 2000
Small Group Leader, Cardiovascular Pharmacology Lead 2 small group sessions per year, 2 hours per session Attended by 5-10 first year medical students
2000
Department of Epidemiology Clinical Epidemiology Seminar 1 hour lecture/25 medical students and fellows (July 17)
2000 - present
Early Renal Insufficiency Teaching Conference, 1 hour per month Conduct monthly conference attended by 1 nurse practitioner, nephrology fellows, 2 additional staff physicians and staff (1 RN, 1dietician, 1 SW, 1 administrative person
2001 - 2003
Department of Medicine Continuing Medical Education Program 1 hour/50-75 guest physicians (June 18)
2005
Ambulatory care conference, University of Maryland 1 hour/20 medical residents (July 29)
2006
Small group March 31st Acid Base, 2 hours/20 medical students
Jeffrey C. Fink, M.D., M.S. Page 6 of 19 2008
Small groups April 1 & 2nd 8-10AM Renal Pathophysiology 2 hours per session/20 medical students per session
2009
Renal Pathophysiology and Therapeutics Small groups March 25, 26, 27, April 1 & 3 2 hours per session/20 medical students per session
2010
Renal Pathophysiology and Therapeutics Small group April 8, 2 hours/20 medical students
Research Mentoring Students 1996
Kennedy Gabregiorgish, 3rd year medical student, 20 hours mentoring
1997
Mark Flasar, 3rd year medical student, 20 hours mentoring
2006
Yonaton Spotler, 3rd year medical student, 20 hours mentoring (see publication)
2008
Lisa Einhorn, 1st year medical student, 20 hours mentoring (see publication)
2008
Maureen Moen, 1st year medical student, 20 hours mentoring (see publication) American Society of Nephrology Student Research Fellow
2009
Erica Chapin, 1st year medical student, 20 hours mentoring (see publication)
2010
Krupa Patel, 1st year medical student, 20 hours mentoring American Society of Nephrology Student Research Fellow
2011
Nizar Dowla, 1st year medical student, 20 hours mentoring American Society of Nephrology Student Research Fellow
2011
Iris Hartley, 1st year medical student, 20 hours mentoring
Residents 1998
Rachel Burdick, 2nd year resident, 20 hrs mentoring (see publications)
1999
Manoj Reddy, 2nd year resident, 20 hrs mentoring (see publications)
Jeffrey C. Fink, M.D., M.S. Page 7 of 19 2000
Daniel Weiner, 3rd year resident, 20 hours mentoring
Fellows 2004 - 2007
Charlotte Jones-Burton, MD, MS Renal Fellow, (see publications) 80 hours mentoring, NRSA Fellow Award Recipient
Faculty 2005 - 2007
Stephen Seliger MD, MS, Assistant Professor (see publications) 80 hours direct mentoring K-23 award recipient
2007 - 2009
Afshin Parsa, MD, MPH, Assistant Professor 60 hours direct mentoring K-12 Institutional award recipient
2010 - present
Clarissa Diamantidis, MD, MS, Assistant Professor 60 hours direct mentoring (to date) Mentoring Committee (currently preparing K-23 or equivalent award)
Grant Support Active Grants 10/01/01 – 09/30/13 Site Investigator, 20% effort (PI: Appel) Chronic Renal Insufficiency Cohort Study NIDDK UO1, DK61022 Annual direct cost (to site): $224,961 Total direct cost (to site): $1,639,923 CRIC is a multi-center cohort study examining the natural history of persons with chronic kidney disease (n = 3939). Dr Fink is the site PI overseeing study activities on 256 local enrollees and serving as a member of the study steering committee. 03/01/06 – 02/30/11 Site Investigator, 2% effort (PI: Hsu) CRIC-Plus Study of advanced chronic renal insufficiency NIDDK R01 DK070939 Annual direct cost (to site): $27000 Total direct cost (to site): $125,000 CRIC-Plus is a sub-cohort ancillary to CRIC examining the natural history of participants in CRIC who proceed to dialysis. Dr Fink is the site PI overseeing study activities on 58 local enrollees.
Jeffrey C. Fink, M.D., M.S. Page 8 of 19 02/01/07 – 06/30/11 Principal Investigator, 5% effort “Changes in myocardial metabolism with anemia management in CKD” Amgen Annual Direct Costs: $127,000 Total Direct Costs: $244,500 This study examines whether correction of the anemia of chronic kidney disease using darbepoietin alters myocardial metabolism as measured using cardiac positron-emission tomography. 9/28/09 – 8/31/11 (no cost extension)
Site Investigator, 1% effort (PI: Grunwald) R-CRIC Retinopathy in chronic renal insufficiency NIDDK R01 DK074151 Annual direct cost (to site): $43313 Total direct cost (to site): $43313 R-CRIC is an ancillary to CRIC to examine fundoscopic eye changes in CRIC participants. Dr Fink oversees this ancillary study activity on CRIC participants at this site.
07/01/10 – 06/30/15 Principal Investigator, 20% effort NIDDK 1R01 DK084017-01A1 (scored at 2nd percentile) “Does under-recognition of kidney disease affect patient safety?” Annual Direct Costs: $340,521 Total Direct Costs: $1,872,962 This grant funds the Safe Kidney Care project which will prospectively evaluate the impact of a Medical ID alert bracelet on chronic kidney disease recognition and assess to what extent this improves the incidence of disease-specific safety events. Will also enroll a parallel cohort tracked for the baseline rate of safety events in the target population. 9/20/11 – 8/31/15
Principal Investigator, 20% effort NIDDK 1R01DK090008-01 (scored at 5th percentile) Do safety events account for adverse outcomes in CKD? Annual Direct Costs: $343,731 Total Direct Costs: $1,189,292 This grant is an epidemiological analysis of data from the NIDDK-funded CRIC study (see NIDDK UO1, DK61022) to identify the frequency of an array of adverse safety events that are pertinent to kidney disease and to determine whether these events account for some portion of poor outcomes in this disease.
Jeffrey C. Fink, M.D., M.S. Page 9 of 19
Pending grants Completed Grants Extramural grants 07/97– 06/98
Principal Investigator, 2.5% effort “Protein Catabolic Rate in the United States” National Kidney Foundation, Maryland Chapter Total award $4000 Total direct cost $4000
07/98 – 06/99
Principal Investigator, 2.5% effort “How Variable is Achieved Dialysis Adequacy of ESRD Patients” National Kidney Foundation, Maryland Chapter Total award $3250 Total direct cost $3250
07/99 – 06/00
Principal Investigator, 10% effort “Chronic Allograft Nephrology: A Single Center Study of its Predictors and Outcomes.” Hoffman-LaRoche Pharmaceuticals Total award $41,300 Total direct cost $34,417
07/99 – 06/01
Principal Investigator, 20% effort “Role of State and Center Effects in Dialysis Adequacy.” American Society of Nephrology- Carl W. Gottschalk Research Award Total Award $150,000 Total direct cost $136,364
09/04 – 07/07
Principal Investigator, 20% effort “Center Effects Influence on Anemia and mortality” NIH/NIDDK 1 R21 DK064126-01A1 Total award $200,000 Direct cost $148,000
09/03 – 08/07
Director, Kidney Disease Research Core, 10% effort Project EXPORT- Comprehensive Centers in Health Disparities NIH/NCMHD 1P60 MD000532-01 (Wilson) Total award: $400,000, Direct cost $ 400,000
05/05 – 04/10
Site Investigator, 2% effort
Jeffrey C. Fink, M.D., M.S. Page 10 of 19 Pulse wave velocity in chronic kidney disease NIDDK R01 DK067390 (Townsend) Annual direct cost (to site): $9000 Total direct cost (to site): $45,000 07/06 – 06//10
Principal Investigator, 5% effort Quality of anemia management and its outcome in the VA Amgen (administered through BREF) Annual Direct Costs: $100,000 Total Direct Costs: $198,000
08/07 – 07/10
Principal Investigator, 20% effort Effect of practice guidelines on care of chronic kidney disease in the VHA NIDDK 1R21DK075675-01A1 Total award $250,000 Direct cost $172,000
Extramural contracts 07/01/01 – 06/30/06 Co-principal Investigator, 10% effort Principal Investigator: Dr Matthew Weir Registry of Simulect Treated Living Transplant Recipients Novartis Pharmaceuticals Total award-$216,000 Total direct cost $180,000 Intramural grants 07/01/98 – 06/30/99 Principal Investigator, 5% effort “Disparity between Maryland and Virginia in Referral of ESRD Patients for Dialysis.” University of Maryland School of Medicine-Pangborn Award Total award: $15000 Total direct: cost $15000 07/01/99 – 06/30/00 Principal Investigator, 5% effort “The Relationship Between Creatinine and Mortality in ESRD Patients” UMB School of Medicine-Pangborn Award Total award: $15000 Total direct cost: $15000 05/01/03 – 06/30/08 Principal Investigator, 10% effort Relationship Between Tobacco and Kidney Disease Maryland Cigarette Restitution Fund
Jeffrey C. Fink, M.D., M.S. Page 11 of 19 Total award: $235,000 Direct cost: $235,000 09/01/05 – 07/30/09 Research Mentor (to Dr Afshin Parsa), 2.5% effort NIH/NCRR 5K12 RR023250 (Shuldiner) Clinical Research Career Development Award Direct cost (to mentor): $5000 annually Publications Peer-reviewed journal articles 1. Politser PE, Powell SH, Fink JC. New method for reporting the source of abnormal activities of LDH in serum. Clinical Chemistry 1986; 32:1517-1524. 2. Fink JC, Schmid CH, Selker HP. A Decision Aid for Referring Patients with Systolic Murmurs for Echocardiography. J Gen Int Med 1994; 9:479-484. 3. Fink JC, Cooper MA, Burkhart KM, McDonald GB, Zager RA. Marked Enzymuria Following Bone Marrow Transplantation: a Correlate of Veno-occlusive Disease Induced Hepatorenal Syndrome. J Am Soc Nephrol 1995; 6:1655-1660. 4. Fink JC, Cooper MA, Zager RA: Hemodialysis induces tubular injury in patients with acute renal failure. Renal Failure, 1996; 18: 947-949. 5. Weir MR, Anderson L, Fink JC, Gabregiorgish K, Schweitzer EJ, Hoehn-Saric E, Klassen DK, Cangro CB, Johnson LB, Kuo PC, Lim JY, Bartlett ST. A novel approach to the treatment of chronic allograft nephropathy. Transplantation, 1997; 64:1706-1710. 6. Roghmann MC, Fink JC, Polish L, Maker T, Brewrink J, Morris JG, Light PD. Colonization with Vancomycin-resistant enterococci in chronic hemodialysis patients. Am J Kidney Dis, 1998; 32:254-257. 7. Fink JC, Leisenring WM, Sherrard DJ, Weiss NS. Risk factors for avascular necrosis following bone marrow transplantation: a case control study. Bone 1998; 22:67-71. 8. Fink JC, Schwartz SM, Bennedetti TJ, Stehman-Breen CO. Increased Risk of Adverse Maternal and Fetal Outcomes Among Women With Renal Disease. Pediatric and Perinatal Epidemiology. 1998; 12:277-287. 9. Schweitzer EJ, Yoon S, Fink J, Wiland A, Anderson L, Kuo PC, Lim JW, Johnson LB, Farney AC, Weir MR, Bartlett ST. Mycophenolate Mofetil reduces the risk of acute rejection less in African-American than in Caucasian kidney recipients. Transplantation 1998; 65:242-248. 10. Drachenberg CB, Papadimitriou JC, Klassen DK, Weir MR, Cangro CB, Fink JC, Bartlett ST. Chronic pancreas allograft rejection: morphologic evidence of progression in needle biopsies and proposal of a grading scheme. Transplantation Proceedings, 1999; 31:614. 11. Fink JC, Armistead N, Turner M, Gardner J, Light P. Hemodialysis adequacy in Network 5: disparity between states and the role of center effects. Am J Kidney Dis, 1999; 33:97-103. 12. Fink JC, Burdick RA, Kurth S, Armistead N, Turner M, Shickle L, Light PD. The significance of serum creatinine values in incident end stage renal disease patients. Am J Kidney Dis 1999; 34: 694-701. 13. Drachenberg CB, Beskow CO, Cangro CB, Bourquin PM, Simsir A, Fink J, Weir MR, Klassen DK, et al. Human polyoma virus in renal allograft biopsies: morphological
Jeffrey C. Fink, M.D., M.S. Page 12 of 19 findings and correlation with urine cytology. Human Pathology 1999; 30, 970-977. 14. Drachenberg CB, Klassen DK, Weir MR, Wiland A, Fink JC, Bartlett ST, Cangro CB, Blahut S, Papadimitriou. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999; 68:396-402. 15. Nogueira JM, Cangro CB, Fink JC, Klassen DK, Gardner J, Schweitzer E, Wiland A, Flowers J, Jacobs S, Cho E, Philosophe B, Bartlett ST, Weir MR. A comparison of recipient renal outcomes with laparoscopic versus open live donor nephrectomy. Transplantation 1999; 67:722-728. 16. Papadimitriou JC, Drachenberg CB, Wiland A, Klassen DK, Fink J, Weir MR, Cangro C, EJ Schweitzer, Bartlett ST. Histologic grading of acute allograft rejection in pancreas needle biopsy. Transplantation, 1999; 66: 1741-1745. 17. Passalacqua JA, Wiland AM, Fink JC, Bartlett ST, Evans DA, Keay S. Increased incidence of postoperative infections associated with peritoneal dialysis in renal transplant recipients. Transplantation 1999; 68:535-540. 18. Weir MR and Fink JC. Post-transplant Diabetes Mellitus: risks versus benefits with current immunosuppressive medications. Am J Kidney Dis; 1999 34:1-14. 19. Weir MR, Fink JC, Hanes DS, Gardner J, Klassen DK, Cangro C, Schweitzer E, Bartlett ST. Chronic allograft nephropathy: effect of cyclosporine reduction and addition of mycophenolate mofetil on progression of renal disease. Transplant Proceedings, 1999; 31: 1296-1287. 20. Fink JC, Gardner JF, Armistead NC, Turner MS, Light PD. Within center correlation in dialysis adequacy. J Clin Epidemiology 2000; 53: 79-85. 21. Jacobs SC, Cho E, Dunkin, BJ, Flowers JL, Schweitzer E, Cangro C, Fink J, Farney A, Philosophe B, Jarrell B, Bartlett ST. Laparoscopic live donor nephrectomy: the University of Maryland 3-YEAR experience. J Urol 2000; 164:1494-1499. 22. Stehman-Breen CO, Miller L, Fink J, Schwartz SM. Preeclampsia and premature labor among women with hematuria. Paediatric and Perinatal Epidemiology 2000; 14:136-140. 23. Fink JC, Blahut SA, Briglia AE, Gardner JF, Light PD. The effect of center versus patientspecific factors on variations in dialysis adequacy. J Am Soc Nephrol 2001; 12: 164-169. 24. Fink JC, Blahut SA, Weir MR, Sawyer R, Henrich WL, Hise MK. The inevitability of renal function loss in patients with hypercreatinemia. Am J Nephrol 2001; 21:386-389. 25. Fink JC, Rochussen J, Blahut SA, Reddy M, Light PD. The use of erythropoietin prior to the initiation of dialysis and its impact on mortality in new end stage renal disease patients. Am J Kidney Dis 2001; 37: 348-355. 26. Stern JM, Sullivan KM, Ott SM, Seidel K, Fink JC, Longton G, Sherrard DJ. Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study. Biol Blood Marrow Transplant 2001; 7: 257-264 27. Weir MR, Rosenberger C, Fink JC. Pilot study to evaluate a water displacement technique to compare effects of diuretics and angiotensin converting enzyme inhibitors to alleviate lower extremity edema due to dihydropyridine calcium channel antagonists. Am J Hypertens 2001; 14: 963-968. 28. Weir MR, Ward MT, Blahut SA, Klassen DK, Cangro CB, Bartlett ST, Fink JC. The long term impact of calcineurin inhibitor reduction or discontinuation in patients with declining kidney function due to chronic allograft nephropathy. Kidney Int 2001; 59: 1567-1573. 29. Fink JC, Blahut SA, Weir MR. Optimal strategies for modeling the reciprocal of creatinine
Jeffrey C. Fink, M.D., M.S. Page 13 of 19 versus time in renal transplant recipients and patients with native chronic kidney disease. Am J Kidney Dis 2002; 39: 753-761. 30. Fink JC, Onuigbo MA, Blahut SA, Christenson RH, Mann D, Bartlett ST, Weir MR. Pretransplant serum C-reactive protein and the risk of chronic allograft nephropathy in renal transplant recipients: a pilot case-control study. Am J Kidney Disease 2002; 39:10961101. 31. Fink JC, Zhan M, Blahut SA, Soucie M, McClellan WM. Measuring the efficacy of a quality improvement program in dialysis adequacy with changes in center effects. J Am Soc Nephrol 2002; 39 2338-2344. 32. Ramos E, Drachenberg CB, Papadimitriou JC, Hamze O, Fink JC, Klassen DK, Drachenberg RC, Wiland A, Wali R, Cangro CB, Schweitzer E, Bartlett ST, Weir MR. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 2002; 13: 214-2151. 33. Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L, Karyekar CS, Eddington ND Weir MR, Henrich WL. Characterization of hepatic cytochrome P4503A in patients with end-stage renal disease. Clin Pharm Therap 2003; 73: 427-434. 34. Feldman, HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, Fink JC, et al., The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol; 2003; 14: S148-S153. 35. Gehr T, Bender F, Fink J, Light P, Elliott K, Shield C, Turner M, Mays C, Parrish J, Armistead N. Improving adequacy of peritoneal dialysis in ESRD Network 5. Adv Perit Dial 2003; 19: 86-92. 36. Ramos E, Drachenberg CB, Portocarrero M, Wali R, Klassen DK, Fink JC, Farney A, Hirsch H, Papadimitriou JC, Cangro CB, Weir MR, Bartlett ST, BK virus nephropathy diagnosis and treatment: experience at the University of Maryland Renal Transplant Program. Clin Transpl 2003: 143-153. 37. Harris AD, Bradham DD, Baumgarten M, Zuckerman IH, Fink JC, Perencevich EN. The use and interpretation of quasi-experimental designs in infectious diseases. Clin Infect Dis 2004; 38:1586-91. 38. Provenzano R, Garcia-Mayol L, Suchinda P, Von Hartitzsch B, Woollen SB, Zabaneh R, Fink JC. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol 2004; 61: 392-405. 39. Weir MR, Blahut SA, Drachenberg C, Young C, Papademitriou J, Klassen DK, Cangro CB, Bartlett ST, Fink JC. Late Calcineurin Inhibitor Withdrawal As A Strategy to Prevent Graft Loss in Patients with Suboptimal Kidney Transplant Function. Am J Nephrol 2004; 24: 379-386. 40. Wiland AM, Fink JC, Weir MR, Philosophe B, Blahut S, Weir MR Jr, Copenhaver B, Bartlett ST. Should Living Unrelated Renal Transplants Receive Antibody Induction? Results of a Clinical Experience Trial. Transplantation 2004; 77: 422-425. 41. Ble A, Fink JC, Woodman RC, Klausner MA, Windham BG, Guralnik JM, Ferrucci L. Renal function, erythropoietin and anemia of older persons: the InChianti Study. Arch Intern Med 2005; 165: 2222-2227. 42. deFilippi C, Fink JC, Nass CM, Loukonen D; Chen C, Christenson R; Pro-B-type natriuretic peptide predicts coronary disease and left ventricular hypertrophy in asymptomatic chronic kidney disease patients not requiring renal replacement therapy. Am J Kidney Dis 2005: 46: 35-44.
Jeffrey C. Fink, M.D., M.S. Page 14 of 19 43. Jones-Burton C, Brown J, Miranda M, Passmore SR, Royak Schaler R, Fink JC “Awareness of the Association Between Smoking and Kidney Disease among African-Americans” JAAMP 2005;16:15-20 44. Jones –Burton C, Seliger SL, Brown J, Stackiewicz L, Doren Hsu V, Fink JC Racial variations in erythropoietic response to epoetin alfa in chronic kidney disease and the impact of smoking. Nephrol Dial Transplant 2005; 20: 2739-2745. 45. Lu WX, Jones-Burton J, Zhan M, Salzber DJ, Moore Jr J, Fink JC. Survival Benefit of Recombinant Human Erythropoietin Administration prior to Onset of End-Stage Renal Disease: Variations across Surrogates for Quality of Care and Time Nephron Clin Pract 2005; 101: c79-c86. 46. McGregor JC, Kim PW, Perencevich EN, Bradham DD, Furuno JP, Kaye KS, Fink JC, Langenberg P, Roghmann MC, Harris AD. The Utility of the Chronic Disease Score and Charlson Comorbidity Index as Comorbidity Measures for use in Epidemiologic Studies of Antibiotic-Resistant Organisms. Am J Epidemiol. 2005; 161: 483-493. 47. Mishra SI, Jones-Burton C, Fink JC, Brown J, Bakris GL, Weir MR. Does dietary salt increase the risk of progression of kidney disease? Curr Hypertens Rep 2005; 7: 385-391. 48. Wali RK, Wang GS, Gottlieb SS, Bellumkonda L, Hansalia R, Ramos E, Drachenberg C, Papadimitriou J, Brisco MA, Blahut S, Fink JC, Fisher ML, Bartlett ST, Weir MR. Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. J Am Coll Card; 2005 45: 1051-1060. 49. Weir MR and Fink JC. Salt Intake and Progression of Chronic Kidney Disease: An overlooked modifiable exposure? A Commentary. Am J Kidney Dis 2005; 45: 176-188. 50. Jones-Burton C, Mishra SI, Fink JC, Brown J, Gossa W, Bakris GL, Weir MR “An In-depth Review of the Evidence Linking Dietary Salt Intake and Progression of Chronic Kidney Disease” Am J Nephrol; 2006 Jun 9;26(3):268-275. 51. Khan IA, Fink J, Nass C, Chen H, Christenson R, deFilippi CR. N-terminal pro-B-type natriuretic Peptide and B-type natriuretic Peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients. Am J Cardiol 2006; 97: 1530-1534. 52. McGregor JC, Perencevich EN, Furono JP, Langenberg P, Flannery K, Zhu J, Fink JC, Bradham DD, Harris AD. Comorbidity risk-adjustment measures were developed and validated for studies of antibiotic-resistant infections. J Clin Epidemiol 2006; 59:1266-73. 53. Fink JC, Hsu VD, Zhan M, Walker LD, Mullins CD, Jones-Burton C, Langenberg P, Seliger SL. Center effects in anemia management of dialysis patients. J Am Soc Nephrol 2007; 18: 646-653. 54. Jones-Burton C, Seliger SL, Scherer R, Mishra S, Brown J, Weir M, Fink JC. Cigarette smoking and incident chronic kidney disease: a systematic review. Am J Neprhol 2007; 27: 342-35. 55. Jones-Burton C, Vessal G, Brown J, Dowling TC, Fink JC. Urinary Cotinine as an Objective Measure of Cigarette Smoking in Chronic Kidney Disease. Nephrol Dial Transplant 2007; 22:1950-4. 56. Spolter YS, Seliger SL, Zhan M, Hsu VD, Walker LD, Fink JC. The relationship between dialysis performance measures: adequacy and anemia management. Am J Kidney Dis 2007; 50: 774-781. 57. Vessal G, Wiland AM, Philosophe B, Fink JC, Weir MR, Klassen DK. Early steroid withdrawal in solitary pancreas transplantation results in equivalent graft and patient
Jeffrey C. Fink, M.D., M.S. Page 15 of 19 survival compared with maintenance steroid therapy. Clin Transplant. 2007; 21:491-7. 58. Seliger SL, Katzel LI, Fink JC, Weir MR, Waldstein SR. Renal function and cardiovascular response to mental stress. Am J Nephrol. 2008; 28:304-10. 59. Seliger SL, Zhan M, Hsu VD, Walker L, Fink JC. Chronic Kidney Disease Adversely Influences Patient Safety. J Am Soc Nephrol. 2008 Dec;19(12):2414-9. 60. Xie D, Joffe MM, Brunelli SM, Beck G, Chertow GM, Fink JC, Greene T, Hsu CY, Kusek JW, Landis R, Lash J, Levey AS, O'Conner A, Ojo A, Rahman M, Townsend RR, Wang H, Feldman HI. A Comparison of Change in Measured and Estimated Glomerular Filtration Rate in Patients with Nondiabetic Kidney Disease. Clin J Am Soc Nephrol; 2008 Sep; 3(5):1332-8. 61. Einhorn LM, Zhan M, Hsu VD, Walker L, Moen MF, Seliger SL, Weir MR, Fink JC. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009; 169(12):1156-1162. 62. Fink JC, Brown J, Hsu VD, Seliger SL, Walker L, Zhan M. CKD as an under-recognized threat to patient safety. Am J Kidney Disease; 2009 53(4): 681-8. 63. Lash JP, Go AS, Appel LJ, He J, Ojo A, Rahman M, Townsend RR, Xie D, Cifelli D, Cohan J, Fink JC, Fischer MJ, Gadegbeku C, Hamm LL, Kusek JW, Landis JR, Narva A, Robinson N, Teal V, and Feldman HI on behalf of the Chronic Renal Insufficiency Cohort Study Group. The Chronic Renal Insufficiency Cohort (CRIC) Study: Baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol 2009; 4: 1302-11. 64. Moen MF, Zhan M, Hsu VD, Walker L, Einhorn LM, Seliger SL, Fink JC. The frequency and significance of hypoglycemia in chronic kidney disease. Clin J Am Soc Nephrol 4: 1121-1127, 2009. 65. Semba RD, Ferrucci L, Fink JC, Sun K, Beck J, Dalal M, Guralnik JM, Fried LP. Advanced Glycation End Products and Their Circulating Receptors and Level of Kidney Function in Older Community-Dwelling Women. Am J Kidney Dis 2009 53: 51-8. 66. Semba RD, Fink JC, Sun K, Bandinelli S, Guralnik JM, Ferrucci L. Carboxymethyl-lysine, an advanced glycation end product, and decline of renal function in older communitydwelling adults. Eur J Nutr; 2009 Feb;48(1):38-44. 67. Chapin E, Zhan M, Hsu VD, Seliger SL, Walker LD, Fink JC. Adverse safety events in chronic kidney disease: the frequency of “multiple hits”. Clin J Am Soc Nephrol; 2010 5: 87-94. 68. Fink JC, Lodge MA, Smith MF, Hinduja A, Brown J, Dinits-Pensy MY, Dilsizian V. PreClinical Myocardial Metabolic Alterations in Chronic Kidney Disease. Cardiology; 2010 116: 160-167. 69. Grunwald, JE, Alexander J, Maguire M, Whittock R, Parker C, McWilliams K, Lo JC, Townsend R, Gadegbeku CA., Lash JP, Fink JC, Rahman M., Feldman H, Kusek J, Ojo,A,. The CRIC Study Group. Prevalence of Ocular Fundus Pathology in Subjects with Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort (CRIC) Study. Clin J Am Soc Nephrol; 2010 5: 867-73. 70. Lawler EV, Gagnon DR, Fink J, Seliger S, Fonda J, Do TP, Gaziano JM, Bradbury BD. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration. Nephrol Dial Transplant; 2010 25: 2237-2244. 71. Seliger SL, Fox KM, Gandra SR, Bradbury B, Hsu VD, Walker LM, Chiou CF, Fink JC. Timing of Erythropoiesis-stimulating agent (ESA) initiation and adverse outcomes in non-
Jeffrey C. Fink, M.D., M.S. Page 16 of 19 dialysis CKD: a propensity-matched observational study Clin J Am Soc Nephrol; 2010 5: 882-8. 72. Semba RD, Fink JC, Sun K, Windham BG, Ferrucci L. Serum Carboxymethyl-Lysine, a Dominant Advanced Glycation End Product, Is Associated With Chronic Kidney Disease: The Baltimore Longitudinal Study of Aging. J Ren Nutr; 2010 20: 74-81. 73. Seliger SL, Zhang A, Weir MR, Walker L, Hsu VD, Parsa A, Diamantidis C, Fink JC. Erythropoiesis-stimulating agents and stroke in chronic kidney disease: a national casecontrol study. Kidney Int 2011 80(3):288-94. 74. Dalal M, Semba RD, Sun K, Crasto C, Varadhan R, Bandinelli S, Fink JC, Guralnik JM, Ferrucci L. Endogenous Secretory Receptor for Advanced Glycation End Products and Chronic Kidney Disease in the Elderly Population. Am J Nephrol 2011 33:313-318. 75. Kop WJ, Seliger SL, Fink JC, Katz R, Odden MC, Fried LF, Rifkin DE, Sarnak MJ, Gottdiener JS. Longitudinal Association of Depressive Symptoms with Rapid Kidney Function Decline and Adverse Clinical Renal Disease Outcomes. Clin J Am Soc Nephrol 2011; 6:834-44. 76. Townsend RR, Anderson AH, Chen J, Gadebegku CA, Feldman HI, Fink JC, et al. for the CRIC Study Investigators Metabolic Syndrome, Components, and Cardiovascular Disease Prevalence in Chronic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Nephrol 2011;33:477-48 77. Weir MR, Townsend RR, Fink JC, Teal V, Anderson C, Appel L, Chen J, He J, Litbarg N, Ojo A, Rahman M, Rosen L, Sozio SM, Steigerwalt S, Strauss L, Joffe MM. Hemodynamic correlates of proteinuria in chronic kidney disease. Clin J Am Soc Nephrol 2011, ePub
Non peer reviewed journal articles 1. 2. 3. 4.
Fink JC, Tucker JC. The artificial heart. Health Matrix 1985. Fink JC, Henrich WL. How important is volume excess in the etiology of hypertension in dialysis patients. Semin Dialysis 1999 12: 303-304. Fink JC, Henrich WL. The outcome of the urban renal patient: The importance of social factors and center effects. Semin Nephrol 2001; 21: 356-361. Fink JC. The effect of CKD therapies on serum potassium levels. Nat Rev Nephrol; 2010 6:633-634.
Editorials 1. 2. 3.
Dilsizian V, Fink JC. Deleterious effect of altered myocardial fatty acid metabolism in kidney disease. JACC 2008; 51: 146-148.2.Fink JC. Do you need to finish school to get a kidney transplant? Am J Kidney Disease 2008; 51: 717-718. Fink JC, Chertow GM. Medication errors: one piece to the patient safety puzzle. Kidney Int; 2009 76: 1123-1125. Fink JC. Chronic Kidney Disease as a Potent Risk Modifier for Coronary Heart Disease in Diabetes Mellitus. JACC Cardiovasc Imaging; 2010; 3: 746-748.
Book Chapters
Jeffrey C. Fink, M.D., M.S. Page 17 of 19 1. 2.
Fink JC. Current outcomes of dialysis patients. Chapter 43, Principles and Practice of Dialysis, Third Edition, ed Henrich WL; 2003 pages 662-672. Fink JC. Current outcomes and quality of care of dialysis patients. Chapter 43, Principles and Practices of Dialysis, Fourth Edition, ed. Henrich WL; 2009 683-694.
Selected abstract publications 1. 2. 3. 4. 5. 6. 7. 8.
9. 10. 11. 12. 13. 14.
Fink JC, Blahut SA, Briglia AE, Gardner JF, Light PD. The effect of center versus patientspecific factors on variations in dialysis adequacy. J Am Soc Nephrol 2000; 11: 230A. Fink JC, Blahut SA, Light PD, McClellan WM. Assessing the impact of a quality improvement effort on dialysis adequacy by measuring changes in center effects. J Am Soc Nephrol 2000; 11: 146A. Fink JC, Blahut SA, Light PD. The use of erthyropoietin prior to the initiation of dialysis and its impact on mortality. J Am Soc Nephrol 2000; 11: 146A. Fink JC, Blahut SA, Weir MR. Geomapping to assess small area variations in transplantation rates as an initial renal replacement therapy. Transplantation 2000; 69; S116. Fink JC, Blahut SA, Weir MR. Small area variations in erythopoietin use prior to initiation of dialysis in Network 5. J Am Soc Nephrol 2000; 11: 145A. Fink JC, Wiland AM, Philosophe B, Blahut SA, Rocchusen JR, Wali RK, Weir MR. The effect of Prograf compared to Neoral on glycemic trends after renal transplantation. Transplantation 2000; 69, S325. Fink JC, Wiland AM, Rocchusen JR, Drachenberg CB, Papadimitriou JP. The increased incidence of BK Polyoma virus in renal transplant recipients treated with Prograf. Transplantation 2000; 69, S385. Philosophe B, Fink JC, Wiland AM, Farney AC, Schweitzer EJ, Colonna JO, Jarrell BE, Krishnamurthi V, Bartlett ST. Low kidney rejection rates with basiliximab induction and delayed introduction of tacrolimus for patients with delayed graft function. Transplantation 2000; 69, S259. Salmanullah M, Sawyer R, Henrich WL, Weir MR, Fink JC, Hise MK. The natural history of an elevated creatinine in a VA population. J Am Soc Nephrol 2000; 11: 164A. Weir MR, Traver M, Blahut SA, Klassen DK, Cangro CB, Bartlett ST, Fink JC. The longterm impact of calcineurin inhibitor reduction or discontinuation in patients with declining kidney function due to chronic allograft nephropathy. Transplantation 2000; 69, S163. Wiland AM, Fink JC, Philosophe B, Farney A, Schweitzer EJ, Colonna JO, Weir MR, Bartlett ST. Cost effective measures to administer Thymoglobulin for induction therapy in pancreas transplant recipients. Transplantation 2000; 69; S408. Wiland AM, Fink JC, Philosophe B, Farney AC, Schweitzer EJ, Colonna JO. Weir MR, Bartlett ST. Experience with Thymoglobulin induction therapy in pancreas transplant recipients. Transplantation 2000; 69; S408. Fink JC, Blahut SA, Weir MR. Is Renal transplantation adequate treatment for the anemia of renal disease? J Am Soc Nephol 2001; 12: 887A. Oniquibo M, Blahut SA, Christenson R, Weir MR, Guitterrez M, Fink JC. Pre-transplant C-reactive protein as a predictor of chronic allograft nephropathy: a case-control study. Am J Transplant 2001; 1: 290A.
Jeffrey C. Fink, M.D., M.S. Page 18 of 19 Major Invited Speeches 1. “Anemia of Chronic Kidney Disease”, University of Virginia Renal Rounds, 8-10 physicians in attendance from renal division. Jan 26, 2001 2. “Benefits of Epoetin alfa in Treating Anemia of Chronic Kidney Disease”. MCPHahnemann CME Program. 50 physicians in attendance including faculty and housestaff from the institution. April 25, 2001 3. “Benefits of Epoetin alfa in Treating Anemia of Chronic Kidney Disease”. Easton Memorial Hospital Grand Rounds. 12 physicians from the hospital in attendance. May 4, 2001 4. “Anemia of Chronic Kidney Disease”. Virginia Assoc. of Family Practice Physicians, Annual Meeting. 100 family practice physicians in attendance. June 18, 2001 5. “Epidemiology of polyomovirus infection in transplantation”. NIH, NIAID Scientific Advisory Conference, Bethesda, Maryland. 25 physician attendees. August 13, 2002 6. “Polyomavirus infection in renal transplantation”. University of Pennsylvania, Transplant Grand Rounds. 15 Physicians in attendance. January 15, 2003 7. “Polyomavirus infection in renal transplantation”. Washington Hospital Center, Transplant Grand Rounds. 20 Physicians in attendance. February 19, 2003 8. “Managing Chronic Kidney Disease”. Perry Point VA Medical Center, Medical Grand Rounds. 20 Physicians in attendance. August 27, 2003 9. “Managing Chronic Kidney Disease”. Washington VA Medical Center, Nephrology Rounds.15 Physicians in attendance. October 1, 2003 10. “Analgesic Nephropathy: recommendations for warning labels”. Staff members of US Senate Government Affairs Committee. Washington DC. 10 Senate staffers present. November 5, 2003 11. “Clinical care of Chronic Kidney Disease”. University of Maryland, Department of Medicine CME program. 100 physicians present. June 9, 2004 12. “Clinical care of Chronic Kidney Disease”. University of Maryland Department of Family Practice CME program. 100 physicians present. July 2, 2004 13. “Baltimore Coalition activities”. National Kidney Disease Education Program, NIH Steering Committee. 30 physicians and attendees present. June 11, 2004 14. “Benefits of a Chronic Kidney Disease clinic”. American Society of Nephrology, Renal Week. St Louis, Missouri. 75 physicians in attendance. October 28, 2004 15. “Chronic Kidney Disease Management in primary care”. Ohio State University Medical Grand Rounds. 60 physicians in attendance. June 30, 2005 16. “Management of Chronic Kidney Disease”. Mercy Medical Center, Baltimore. 50 physicians in attendance. January 11, 2006 17. “Center effects in hemodialysis”. Mid-Atlantic Nephrology Young Investigators Forum. Baltimore, MD. 25 physicians in attendance. March 15, 2006 18. “Chronic kidney disease management: Same old swan song?” National Capital Nephrology Forum. National Naval Medical Center, Bethesda MD. 25 physicans in attendance. April 12, 2006 19. “Promoting the Partnership”. Symposium on Transplant and Dialysis Center Relationships. Maryland Commission on Kidney Disease. UMBC Technology Center. 75 Health Care Providers in Attendance. October 3, 2006
Jeffrey C. Fink, M.D., M.S. Page 19 of 19 20. “Chronic Kidney Disease”. University of Maryland Mini-Medical School College of Southern Maryland. 15 participants. October 21, 2006 21. “Chronic kidney disease management: Same old swan song?” Grand rounds, Uniformed Services University of Health Sciences, Andrews Air Force Base. 50 participants. October 27, 2006 22. “Chronic kidney disease management: Same old swan song?” Renal Grand Rounds, JHUBayview Medical Center. 20 participants. December 6, 2006 23. “Kidney Disease”. University of Maryland Statewide Health Network. Heritage United Church of Christ, Baltimore, MD. 35 attendees. June 2, 2007 24. “Irreversible Renal Failure: Challenges and Considerations with Dialysis and Transplantation” Learning Institute for Management of Chronic Kidney Disease, Boston, Massachusetts. 40 attendees. October 24, 2007 25. “View from a CRIC (Chronic Renal Insufficiency Cohort Study) Clinical Center”. Chronic Kidney Disease-Japanese CRIC meeting at the American Society of Nephrology conference, San Francisco, California. 40 attendees present. November 3, 2007 26. “The Relationship between Smoking and Chronic Kidney Disease (CKD): Developing Evidence Using Biological and Epidemiological Methods”. University of Maryland Statewide Health Network, Baltimore, MD. 100 physicians and attendees present. November 19, 2007 27. “Update on Chronic Kidney Disease”. University of Maryland Family Practice Grand Rounds 28. 35 participants. December 5, 2007 29. “Chronic Kidney Disease and Patient Safety”. Renal Disease Interest Group. Welch Center, Johns Hopkins University. 20 participants. January 23, 2008 30. “Natuiretic peptides in ESRD. American Society of Nephrology Annual Meeting, Philadelphia, PA. 300 participants. November 6, 2008 31. “Disease specific safety indicators in CKD”. Renal Disease Interest Group. Welch Center, Johns Hopkins University. 20 participants. May 27, 2009 32. “Walk the Line”. Challenge of Hypoglycemia in the CKD patient with Diabetes. National Kidney Foundation. Case-based CME webcast. March 1, 2010“Chronic kidney disease as a crucible of patient safety”. Welch Center Rounds, Johns Hopkins University. 40 participants. December 8, 2010 33. “Chronic kidney disease as a crucible of patient safety”. George Washington University, Department of Medicine, Grand rounds. 150 participants. August 25, 2011